CorrespondenceA controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
References (11)
- et al.
Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance
J Hepatol
(1998) - et al.
Fatty liver hepatitis and cirrhosis in obese patients
Am J Med
(1979) - et al.
Alcohol-like liver disease in non-alcoholics. A clinical and histologic comparison with alcohol-induced liver injury
Gastroenterology
(1988) - et al.
Nonalcoholic steatohepatitis: an expanded clinical entity
Gastroenterology
(1994) - et al.
Profile of an urban hospital-based practice
Hepatology
(1996)
There are more references available in the full text version of this article.
Cited by (285)
The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics
2022, Experimental and Molecular PathologyRoles of peroxisome proliferator-activated receptor α in the pathogenesis of ethanol-induced liver disease
2020, Chemico-Biological InteractionsCitation Excerpt :In fact, PPARα agonists have been tested in patients with NAFLD, a liver disease sharing many similarities with ALD such as the histopathological characteristics, hepatotoxicity via oxidative and ER stress, and the pivotal roles of the innate immune system [131]. Although the ability of PPARα agonists to counteract steatohepatitis and fibrosis appeared prominent in murine models of NAFLD [44], clinical trials showed that PPARα agonists did not improve hepatic steatosis in patients with NAFLD [132–138] (Table 1). However, the expression of hepatic PPARα was found to be reduced in patients with NAFLD and decline of PPARα expression was positively correlated with the NAFLD activity score and fibrosis stage [139].
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
2020, European Journal of Medicinal ChemistryPeroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease
2019, Journal of Clinical and Experimental Hepatology
Copyright © 1999 Published by Elsevier Ireland Ltd.